p21~(ras) Expression in Endometrium of Postmenopausal Breast Cancer Patients Treated with Tamoxifen.

Xu Xiaowen,Qu Wanglei,Zheng Min,Dong Jianda,Qiu Shaofei

2011-01-01

Abstract:Objective To investigate the expression of p21ras in endometrium of postmenopausal women taking tamoxifen(TAM) for breast cancer,and study the relationship between ras mutation and tamoxifen-related endometrial lesion.Methods A prospective study was performed in 85 cases of breast cancer patients who had operation in the 2nd Affiliated Hospital of Wenzhou medical college from January 2005 to October 2008.Endometrial tissues were taken from the breast cancer patients and diagnosed and grouped through HE,including 20 cases of normal endometrium before TAM treatment,20 cases of normal endometrium after over 3 years of TAM treatment and 22 cases of endometrial polyps after TAM treatment.Eighty cases of postmenopausal patients were rolled as control group,including 30 cases of normal endometrial tissue from prolapse uterus,30 cases of non-Tamoxifen-treated polyps and 20 cases of adenocarcinoma of endometrium.Immunohistochemistry(sp) was used to detect the p21ras in these tissues.Results In breast cancer group,the positive rate of p21ras expression in tamoxifen-treated endometrium and polyps were 25.5%(5/20) and 27.27%(6/22) respectively.Comparing with the non-tamoxifen-treated endometrium and adenocarcinoma of endometrium,the difference was significant(P<0.05).In control group,the positive rate of p21ras expression in normal endometrium,endometrial polyps and adenocarcinoma of endometrium were 3.33%(1/30),13.33%(4/30),70%(14/20)respectively.A progressive increase was along with the grade of the lesion(P<0.05).Conclusion The overexpression of p21ras in endometrium had close relation with endometrial lesion.Taking tamoxifen may cause the overexpression of p21ras,which may be a possible reason of the development of endometrial carcinoma in postmenopausal women who have been treated with TAM.